Akanda (AKAN) Competitors

$24.31 -1.18 (-4.63%)

Closing price 05/13/2026 04:00 PM Eastern

Extended Trading

$24.26 -0.05 (-0.20%)

As of 05/13/2026 07:56 PM Eastern

AKAN vs. CING, IMMP, IMA, IBIO, and BYSI

Should you buy Akanda stock or one of its competitors? MarketBeat compares Akanda with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Akanda include Cingulate (CING), Prima BioMed (IMMP), ImageneBio (IMA), iBio (IBIO), and BeyondSpring (BYSI). These companies are all part of the "pharmaceutical products" industry.

How does Akanda compare to Cingulate?

Cingulate (NASDAQ:CING) and Akanda (NASDAQ:AKAN) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, valuation, institutional ownership, dividends, media sentiment and profitability.

Akanda's return on equity of 0.00% beat Cingulate's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cingulate	N/A	-509.72%	-172.37%
Akanda	N/A	N/A	N/A

Akanda has higher revenue and earnings than Cingulate.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cingulate	N/A	N/A	-$22.45M	-$4.32	N/A
Akanda	$840K	15.34	-$4.10M	N/A	N/A

Cingulate has a beta of -0.81, indicating that its share price is 181% less volatile than the broader market. Comparatively, Akanda has a beta of 14.49, indicating that its share price is 1,349% more volatile than the broader market.

In the previous week, Akanda had 4 more articles in the media than Cingulate. MarketBeat recorded 6 mentions for Akanda and 2 mentions for Cingulate. Cingulate's average media sentiment score of 0.94 beat Akanda's score of 0.64 indicating that Cingulate is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cingulate	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Akanda	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cingulate presently has a consensus price target of $34.50, indicating a potential upside of 601.22%. Given Cingulate's stronger consensus rating and higher possible upside, equities research analysts clearly believe Cingulate is more favorable than Akanda.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cingulate	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Akanda	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

41.3% of Cingulate shares are held by institutional investors. Comparatively, 1.0% of Akanda shares are held by institutional investors. 4.3% of Cingulate shares are held by insiders. Comparatively, 20.4% of Akanda shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Akanda beats Cingulate on 7 of the 12 factors compared between the two stocks.

How does Akanda compare to Prima BioMed?

Prima BioMed (NASDAQ:IMMP) and Akanda (NASDAQ:AKAN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, risk, dividends, media sentiment and institutional ownership.

Prima BioMed has a beta of 2.24, suggesting that its stock price is 124% more volatile than the broader market. Comparatively, Akanda has a beta of 14.49, suggesting that its stock price is 1,349% more volatile than the broader market.

Prima BioMed presently has a consensus price target of $5.50, suggesting a potential upside of 1,085.60%. Given Prima BioMed's stronger consensus rating and higher possible upside, analysts plainly believe Prima BioMed is more favorable than Akanda.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prima BioMed	1 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75
Akanda	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Net Margins	Return on Equity	Return on Assets
Prima BioMed	N/A	N/A	N/A
Akanda	N/A	N/A	N/A

2.3% of Prima BioMed shares are held by institutional investors. Comparatively, 1.0% of Akanda shares are held by institutional investors. 3.1% of Prima BioMed shares are held by company insiders. Comparatively, 20.4% of Akanda shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Akanda has lower revenue, but higher earnings than Prima BioMed.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prima BioMed	$6.69M	10.22	-$39.78M	N/A	N/A
Akanda	$840K	15.34	-$4.10M	N/A	N/A

In the previous week, Prima BioMed had 16 more articles in the media than Akanda. MarketBeat recorded 22 mentions for Prima BioMed and 6 mentions for Akanda. Akanda's average media sentiment score of 0.64 beat Prima BioMed's score of 0.10 indicating that Akanda is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prima BioMed	0 Very Positive mention(s)	2 Positive mention(s)	18 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Akanda	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Prima BioMed and Akanda tied by winning 5 of the 10 factors compared between the two stocks.

How does Akanda compare to ImageneBio?

Akanda (NASDAQ:AKAN) and ImageneBio (NASDAQ:IMA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and profitability.

Akanda has a beta of 14.49, meaning that its share price is 1,349% more volatile than the broader market. Comparatively, ImageneBio has a beta of 0.73, meaning that its share price is 27% less volatile than the broader market.

ImageneBio has a consensus price target of $26.50, indicating a potential upside of 359.27%. Given ImageneBio's stronger consensus rating and higher probable upside, analysts clearly believe ImageneBio is more favorable than Akanda.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Akanda	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
ImageneBio	2 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.00

Akanda's return on equity of 0.00% beat ImageneBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Akanda	N/A	N/A	N/A
ImageneBio	N/A	-38.96%	-34.60%

1.0% of Akanda shares are held by institutional investors. Comparatively, 75.0% of ImageneBio shares are held by institutional investors. 20.4% of Akanda shares are held by company insiders. Comparatively, 5.9% of ImageneBio shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Akanda has higher revenue and earnings than ImageneBio.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Akanda	$840K	15.34	-$4.10M	N/A	N/A
ImageneBio	$800K	76.81	-$45.35M	-$5.79	N/A

In the previous week, ImageneBio had 2 more articles in the media than Akanda. MarketBeat recorded 8 mentions for ImageneBio and 6 mentions for Akanda. Akanda's average media sentiment score of 0.64 beat ImageneBio's score of -0.13 indicating that Akanda is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Akanda	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ImageneBio	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Akanda beats ImageneBio on 7 of the 13 factors compared between the two stocks.

How does Akanda compare to iBio?

iBio (NASDAQ:IBIO) and Akanda (NASDAQ:AKAN) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, dividends, valuation, profitability, earnings, institutional ownership and media sentiment.

Akanda's return on equity of 0.00% beat iBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iBio	N/A	-64.97%	-54.58%
Akanda	N/A	N/A	N/A

iBio currently has a consensus price target of $4.75, indicating a potential upside of 206.45%. Given iBio's stronger consensus rating and higher probable upside, analysts clearly believe iBio is more favorable than Akanda.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iBio	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	3 Strong Buy rating(s)	3.17
Akanda	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

iBio has a beta of 1.23, suggesting that its stock price is 23% more volatile than the broader market. Comparatively, Akanda has a beta of 14.49, suggesting that its stock price is 1,349% more volatile than the broader market.

In the previous week, Akanda had 1 more articles in the media than iBio. MarketBeat recorded 6 mentions for Akanda and 5 mentions for iBio. iBio's average media sentiment score of 0.98 beat Akanda's score of 0.64 indicating that iBio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
iBio	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Akanda	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

7.9% of iBio shares are owned by institutional investors. Comparatively, 1.0% of Akanda shares are owned by institutional investors. 2.8% of iBio shares are owned by insiders. Comparatively, 20.4% of Akanda shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Akanda has higher revenue and earnings than iBio.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iBio	$400K	140.04	-$18.38M	-$0.58	N/A
Akanda	$840K	15.34	-$4.10M	N/A	N/A

Summary

iBio and Akanda tied by winning 7 of the 14 factors compared between the two stocks.

How does Akanda compare to BeyondSpring?

BeyondSpring (NASDAQ:BYSI) and Akanda (NASDAQ:AKAN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings, media sentiment and valuation.

Company	Net Margins	Return on Equity	Return on Assets
BeyondSpring	N/A	N/A	-12.39%
Akanda	N/A	N/A	N/A

40.3% of BeyondSpring shares are owned by institutional investors. Comparatively, 1.0% of Akanda shares are owned by institutional investors. 29.3% of BeyondSpring shares are owned by insiders. Comparatively, 20.4% of Akanda shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeyondSpring	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Akanda	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Akanda had 1 more articles in the media than BeyondSpring. MarketBeat recorded 6 mentions for Akanda and 5 mentions for BeyondSpring. BeyondSpring's average media sentiment score of 0.93 beat Akanda's score of 0.64 indicating that BeyondSpring is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BeyondSpring	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Akanda	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BeyondSpring has a beta of 0.41, suggesting that its share price is 59% less volatile than the broader market. Comparatively, Akanda has a beta of 14.49, suggesting that its share price is 1,349% more volatile than the broader market.

BeyondSpring has higher revenue and earnings than Akanda.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeyondSpring	$1.75M	34.07	-$1.01M	-$0.15	N/A
Akanda	$840K	15.34	-$4.10M	N/A	N/A

Summary

BeyondSpring beats Akanda on 6 of the 9 factors compared between the two stocks.

Get Akanda News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AKAN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AKAN vs. The Competition

Export

Metric	Akanda	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$13.62M	$8.12B	$6.30B	$12.20B
Dividend Yield	N/A	2.50%	2.79%	5.30%
P/E Ratio	N/A	18.19	20.99	25.65
Price / Sales	15.34	8.35	555.98	78.93
Price / Cash	N/A	16.76	42.94	55.34
Price / Book	0.12	3.75	9.70	6.66
Net Income	-$4.10M	$223.05M	$3.55B	$333.63M
7 Day Performance	-34.63%	-2.05%	-0.56%	-0.11%
1 Month Performance	676.68%	3.40%	1.17%	3.94%
1 Year Performance	-70.19%	1.89%	41.20%	36.07%

Akanda Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AKAN Akanda	0.6361 of 5 stars	$24.31 -4.6%	N/A	-71.7%	$13.62M	$840K	N/A	110	Short Interest Increase Gap Down
CING Cingulate	2.6139 of 5 stars	$5.33 +7.0%	$34.50 +547.3%	+25.8%	$65.29M	N/A	N/A	20
IMMP Prima BioMed	2.5347 of 5 stars	$0.44 -3.7%	$5.50 +1,143.2%	-75.5%	$65.20M	$6.69M	N/A	2,021	Trending News Short Interest Increase
IMA ImageneBio	2.7784 of 5 stars	$6.08 +4.3%	$26.50 +335.9%	-58.5%	$64.75M	$800K	N/A	70	Earnings Report Analyst Forecast
IBIO iBio	4.4267 of 5 stars	$1.77 +9.9%	$4.75 +168.4%	N/A	$63.97M	$400K	N/A	100	Earnings Report Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AKAN) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Akanda (AKAN) Competitors